Promotoren

Prof. Karin Vanderkerken
Hematologie en Immunologie (HEIM)
Vrije Universiteit Brussel

Prof. Ivan Van Riet
Hematologie en Immunologie (HEIM)
Vrije Universiteit Brussel

Leden van de examencommissie

Prof. Peter Croucher
Department of Human Metabolism
Academic Unit of Bone Biology
University of Sheffield Medical School
United Kingdom

Prof. Fritz Offner
Department of Stem Cell Biology and Therapy of Lymphoid malignancies, University Hospital Gent
Universiteit Gent

Dr. Ann Van De Velde
Department of Hematology, University Hospital Antwerp
Universiteit Antwerpen

Dr. Jo Van Ginderachter
Department of Molecular and Cellular Interactions
Vrije Universiteit Brussel

Prof. Leo Van Grunsven
Department of Cell Biology
Vrije Universiteit Brussel

Prof. Jacques De Grêve, voorzitter
Department of Medical and Molecular Oncology
Vrije Universiteit Brussel

Doctoraat in de Medische Wetenschappen
Academiejaar 2009-2010

UITNODIGING
Voor de openbare verdediging van het doctoraatsproefschrift van

Elke DE BRUYNE

Donderdag 28 januari 2010
Multiple myeloma (MM) is a plasma cell (PC) malignancy hallmarked by uncontrolled accumulation of monoclonal PCs within the bone marrow (BM). The BM microenvironment provides a sanctuary for the MM cells to survive, proliferate and evade drug-induced cell death due to intimate, reciprocal interactions between the MM cells and the surrounding cells. Based on our enhanced understanding of the pivotal role of this intimate reciprocal relationship in MM carcinogenesis, numerous new molecular targets were identified and novel therapies, including thalidomide, bortezomib and lenalidomide, were derived. Although the introduction of these drugs resulted in a significant improvement in the overall survival, patients inevitably relapse, underscoring the urgent need for new potential targets. BM endothelial cells (BMEC) are one of the surrounding cell types actively involved in MM disease progression. In short, BMEC are involved in the homing of the MM cells, angiogenesis, osteoclastogenesis and induce survival and drug resistance of the tumor cells. In this work we investigated the BMEC induced modulation of the gene expression of the MM cells in an attempt to find new molecular targets. We found that BMEC are actively involved in MM progression by regulating expression of the tetraspanins CD9 and CD53 and the pro-apoptotic molecule Bim in MM cells and this either through direct cell contact and/or the secretion of soluble factors. These data provide new molecular targets and furthermore support the rationale for using therapeutic agents in MM that directly target BMEC in combination with both conventional and novel therapies.

Elke De Bruyne was born in 1981 in Asse. Already in childhood, her interest was sparked for science and research. In 1999 she began her studies in biomedical sciences at the Vrije Universiteit Brussel. In her last year, she prepared a master thesis on the role of TIMP-2 in multiple myeloma progression at the department of Hematology and Immunology and obtained her diploma with greatest distinction in 2003. Dr. Els Van Valckenborgh trained her in the basics of cellular and molecular biology, which more and more gained her interest. She began her doctorate in the same lab on a OZR-VUB scholarship, supervised by Prof. Ben Van Camp and Prof. Karin Vanderkerken. Several international collaborations proved to be fruitful. Her work resulted in several publications and awards, among which the award of the Belgian Hematology Society for best poster presentation. Recently, she was the laureate of the Catherina Weekers Fund 2009 granted by the Koning Boudewijn Stichting.